Navigation Links
Nuvilex Launches Video Marketing Campaign
Date:6/1/2009

CHERRY HILL, N.J., June 1 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company is now airing the first in a series of videos to promote the company and its products. Chairman and CEO Martin Schmieg leads off with an overview of the company's innovative and diverse product lines. This video is now running on the Nuvilex website at www.nuvilex.com and will be featured in corporate presentations and the Company's business development efforts.

Next up is a video commercial to promote Nuvilex' Last Shot Hangover Remedy. This new product eases hangover symptoms and is expected to launch Q3 2009 (July) in North America and Q4 2009 (October) worldwide. The Last Shot Hangover Remedy will air on various platforms including television, movie previews, and the Internet. Miller + Partners has been engaged to produce Nuvilex' video campaign.

About Miller + Partners

For over two decades, the consulting team at MILLER+PARTNERS has helped hundreds of top companies leverage the screen to communicate better, build brand awareness and heighten the users experience. Our Powermercial(TM) products enable our clients to reach across the social and sharing networks with engaging, entertaining and market focused video. For more information about Miller + Partners please visit us at www.GreatVideoSells.com.

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Stephanie Carrington/Amy Glynn
    The Ruth Group
    Ph: 646-536-7017/7023
    Email: scarrington@theruthgroup.com
    Email: aglynn@theruthgroup.com


    Press Contacts:

    Pat Arcand
    Arcand & Madison Public Relations
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
2. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
3. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
4. Nuvilex, Inc. Announces Monthly Investor Conference Call
5. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
6. Nuvilex, Inc. Announces Investor Conference Call and Open House
7. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
8. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
9. Nuvilex Provides Conference Call Replay Information
10. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
11. Nuvilex Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... and Shelton, CT (PRWEB) , ... May 02, 2016 , ... ... President and Owner of New England Low Vision and Blindness (NELV&B) , announces ... add more flexibility and convenience for people with vision impairments to get assessments, hands-on ...
(Date:5/1/2016)... ... May 01, 2016 , ... ... that gives new mothers a better understanding of what to expect after they ... Adjusting to baby postpartum, · The blues and depression, · Breastfeeding beyond postpartum ...
(Date:4/30/2016)... ... April 30, 2016 , ... Create ... Abstract users can distort and manipulate three-dimensional shapes with ease all within ... ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published ... her enthusiasm for Botox and lip injections, which she underwent in order to feel ... Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: